Tafinlar Tablet, For Suspension
NDC Package 0078-1154-21

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Tafinlar (dabrafenib) tablets is dabrafenib may be used alone or in combination with another medication (trametinib) to treat a type of skin cancer (melanoma). This formulation utilizes a tablet, for suspension delivery system. Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-1154 and is authorized under FDA application NDA217514.

Identification & Billing

NDC Package Code
0078-1154-21
Package Description
210 TABLET, FOR SUSPENSION in 1 BOTTLE
Product Code
0078-1154
11-Digit Billing Format
00078115421
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
210 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tafinlar
Non-Proprietary Name
Dabrafenib
Substance Name
Dabrafenib Mesylate
Dosage Form
Tablet, For Suspension - A tablet that forms a suspension when placed in a liquid (formerly referred to as a ‘dispersible tablet’).
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DABRAFENIB MESYLATE 10 mg/1
Pharmacologic Class
Usage Information
Dabrafenib may be used alone or in combination with another medication (trametinib) to treat a type of skin cancer (melanoma). It is also used with trametinib to treat thyroid cancer and a type of lung cancer (non-small cell lung cancer-NSCLC). Dabrafenib works by slowing the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Novartis Pharmaceuticals Corporation
Product Type
Human Prescription Drug
FDA Application #
NDA217514
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-16-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0078-1154-21 identifies a specific commercial package of 210 tablet, for suspension in 1 bottle of Tafinlar, a human prescription drug labeled by Novartis Pharmaceuticals Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 210 billable units per package. This tablet, for suspension is formulated for oral use and contains dabrafenib mesylate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on March 16, 2023. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Dabrafenib may be used alone or in combination with another medication (trametinib) to treat a type of skin cancer (melanoma). It is also used with trametinib to treat thyroid cancer and a type of lung cancer (non-small cell lung cancer-NSCLC). Dabrafenib works by slowing the growth of cancer cells.

How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078115421. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 210 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0078-1154-21
11-Digit CMS (5-4-2)
00078-1154-21

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.